Table 2.
Baseline characteristics by third dose vaccine allocation and priming vaccine schedule, group A
|
Prime with ChAd/ChAd |
Prime with BNT/BNT |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Control (n=109) | ChAd (n=111) | NVX (n=115) | NVX half (n=108) | Control (n=118) | ChAd (n=109) | NVX (n=114) | NVX half (n=112) | ||
| Age, years | |||||||||
| Mean (SD) | 64·0 (14·0) | 63·7 (14·1) | 63·5 (13·7) | 61·8 (15·1) | 63·1 (16·9) | 61·9 (16·6) | 62·1 (16·4) | 62·9 (16·0) | |
| Median (IQR) | 68·1 (55·1–75·9) | 67·8 (52·2–75·7) | 65·3 (52·6–74·1) | 65·8 (49·9–75·6) | 62·4 (49·4–78·5) | 61·9 (46·5–76·3) | 62·7 (48·0–75·5) | 62·2 (49·9–77·3) | |
| Intervals between first and second doses, days | 68·0 (59·0–76·0) | 69·0 (61·0–76·0) | 68·0 (60·0–76·0) | 70·0 (62·8–77·0) | 41·0 (21·0–68·8) | 34·0 (21·0–65·0) | 42·0 (23·2–65·5) | 56·0 (28·0–70·0) | |
| Intervals between second and third doses, days | 78·0 (72·0–86·0) | 78·0 (73·0–84·5) | 76·0 (72·0–84·5) | 77·0 (71·0–85·0) | 104·5 (95·2–146·0) | 110·0 (92·0–148·0) | 104·5 (93·0–146·8) | 100·0 (91·8–134·8) | |
| Age groups, years | |||||||||
| <70 | 57 (52·3%) | 59 (53·2%) | 63 (54·8%) | 59 (54·6%) | 66 (55·9%) | 64 (58·7%) | 65 (57·0%) | 67 (59·8%) | |
| ≥70 | 52 (47·7%) | 52 (46·8%) | 52 (45·2%) | 49 (45·4%) | 52 (44·1%) | 45 (41·3%) | 49 (43·0%) | 45 (40·2%) | |
| Gender | |||||||||
| Female | 54 (49·5%) | 54 (48·6%) | 61 (53·0%) | 58 (53·7%) | 69 (58·5%) | 57 (52·3%) | 65 (57·0%) | 67 (59·8%) | |
| Male | 55 (50·5%) | 57 (51·4%) | 54 (47·0%) | 50 (46·3%) | 49 (41·5%) | 52 (47·7%) | 49 (43·0%) | 45 (40·2%) | |
| Occupation | |||||||||
| Health worker | 31 (28·4%) | 31 (27·9%) | 40 (34·8%) | 40 (37·0%) | 57 (48·3%) | 53 (48·6%) | 59 (51·8%) | 53 (47·3%) | |
| Other | 78 (71·6%) | 80 (72·1%) | 75 (65·2%) | 68 (63·0%) | 61 (51·7%) | 56 (51·4%) | 55 (48·2%) | 59 (52·7%) | |
| Ethnicity | |||||||||
| White | 107 (98·2%) | 105 (94·6%) | 107 (93·0%) | 103 (95·4%) | 106 (89·8%) | 102 (93·6%) | 109 (95·6%) | 107 (95·5%) | |
| Black | 0 | 0 | 1 (0·9%) | 1 (0·9%) | 1 (0·8%) | 0 | 0 | 0 | |
| Asian | 2 (1·8%) | 4 (3·6%) | 3 (2·6%) | 2 (1·9%) | 10 (8·5%) | 6 (5·5%) | 5 (4·4%) | 2 (1·8%) | |
| Mixed | 0 | 2 (1·8%) | 0 | 0 | 1 (0·8%) | 1 (0·9%) | 0 | 0 | |
| Other | 0 | 0 | 3 (2·6%) | 2 (1·9%) | 0 | 0 | 0 | 3 (2·7%) | |
| Not given | 0 | 0 | 1 (0·9%) | 0 | 0 | 0 | 0 | 0 | |
| Comorbidities | |||||||||
| Cardiovascular | 36 (33·0%) | 36 (32·4%) | 41 (35·7%) | 35 (32·4%) | 37 (31·4%) | 31 (28·4%) | 35 (30·7%) | 35 (31·2%) | |
| Respiratory | 19 (17·4%) | 13 (11·7%) | 15 (13·0%) | 24 (22·2%) | 14 (11·9%) | 13 (11·9%) | 15 (13·2%) | 18 (16·1%) | |
| Diabetes | 8 (7·3%) | 12 (10·8%) | 14 (12·2%) | 11 (10·2%) | 11 (9·3%) | 7 (6·4%) | 7 (6·1%) | 12 (10·7%) | |
Data are median (IQR) or n (%), unless otherwise stated. There were three participants missing on occupation and five participants missing on ethnicity, which were not included in this table. ChAd=ChAdOx1 nCoV-19 vaccine, Oxford–AstraZeneca. BNT=BNT162b2 vaccine, Pfizer–BioNTech. Control=quadrivalent meningococcal conjugate vaccine. NVX=NVX-CoV2373 vaccine, Novavax. NVX half=half dose of NVX-CoV2373 vaccine.